ReviewSurvey of ophthalmology
Ocular graft-versus-host disease (oGVHD): From A to Z.
Review in Survey of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Long-term clinical outcomes in chronic ocular graft-versus-host disease: a retrospective cohort study.Eye (London, England) · 2026Article
- Immunological Interplay at the Ocular Surface of Stevens-Johnson Syndrome, Ocular Cicatricial Pemphigoid, and Ocular Graft Versus Host Disease.Investigative ophthalmology & visual science · 2026Review
- Patient-reported outcomes in chronic GVHD: instruments, clinical utility, and survivorship integration.Journal of patient-reported outcomes · 2026Review
- Current Diagnosis and Management of Ocular Graft-Versus-Host Disease at a Tertiary Cancer Center.Journal of clinical medicine · 2026Review
- Amniotic Membrane-Assisted Corneal Transplantation in Ocular Perforation Due to GVHD: A Case Report.Journal of clinical medicine · 2026Article
- Clinical burden of dry eye disease in patients with ocular graft versus host disease.Academia medicine and health · 2026Article
- Sutureless Amniotic Membrane Grafting in the Management of Corneal Perforations Associated with Severe Ocular Surface Disease.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Advances in nanomedicine-based retinal drug delivery: mechanisms and translational applications.Journal of nanobiotechnology · 2025Review
- Corneal subbasal nerve alterations and tear cytokine associations in ocular chronic graft-versus-host disease.Frontiers in medicine · 2025Article
- Current status, challenges, and integration pathways of biomarker classification systems in graft-versus-host disease: a preliminary exploration.Frontiers in medicine · 2025Review
- Serum Pyroptosis-Related Cytokines as Biomarkers for Diagnostic Assessment and Risk Stratification of Ocular Graft-versus-Host Disease: A Case-Control Study.Journal of inflammation research · 2025Article
- Evolving therapeutic paradigms in ocular graft-versus-host disease.Eye (London, England) · 2024Article
- A review of the application of in-vivo confocal microscopy on conjunctival diseases.Eye and vision (London, England) · 2024Review
- Advances in the ocular complications after hematopoietic stem cell transplantation.Annals of hematology · 2024Review
- Review
- Advances in Extracellular-Vesicles-Based Diagnostic and Therapeutic Approaches for Ocular Diseases.ACS nano · 2024Review
- Early intervention with oral mucosal barrier Protective agents in chronic oral graft-versus-host disease: a retrospective cohort study.BMC oral health · 2024Article
- Remarkable improvement of symptoms and signs of severe dry eye treated by ocular immersion hydrotherapy.Clinical case reports · 2024Article
- A novel severity scoring system for murine ocular graft versus host disease and its correlation with CD3The ocular surface · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Allogeneic hematopoietic stem cell transplantation is a definitive therapy for a variety of disorders. One of the complications is acute graft-versus-host disease (aGVHD), which has a high mortality rate. Patients can also develop chronic graft-versus-host disease (cGVHD), a more indolent yet afflicting condition that affects up to 70% of patients. Ocular involvement (oGVHD) is one of the most prevalent presentations of cGVHD and can manifest as dry eye disease, meibomian gland dysfunction, keratitis, and conjunctivitis. Early recognition of ocular involvement using regular clinical assessments as well as robust biomarkers can aid in better management and prevention. Currently, the therapeutic strategies for the management of cGVHD, and oGVHD in particular, have mainly focused on the control of symptoms. There is an unmet need for translating the preclinical and molecular understandings of oGVHD into clinical practice. Herein, we have comprehensively reviewed the pathophysiology, pathologic features, and clinical characteristics of oGVHD and summarized the therapeutic landscape available to combat it. We also discuss the direction of future research regarding a more directed delineation of pathophysiologic underpinnings of oGVHD and the development of preventive interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.